دورية أكاديمية
Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study
| العنوان: | Real‐world effectiveness and persistence of golimumab as second‐line anti‐TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO‐BEYOND, a 12‐month prospective observational study |
|---|---|
| المؤلفون: | D'Angelo, Salvatore, Tirri, Enrico, Giardino, Angela Maria, DeRosa, Tiziana, Matucci‐Cerinic, Marco, Dagna, Lorenzo, Santo, Leonardo, Ciccia, Francesco, Frediani, Bruno, Govoni, Marcello, Pallavicini, Francesca Bobbio, Grembiale, Rosa Daniela, Sedie, Andrea Delle, Mulè, Rita, Cantatore, Francesco Paolo, Foti, Rosario, Gremese, Elisa, Conigliaro, Paola, Salaffi, Fausto, Viapiana, Ombretta, Cauli, Alberto, Giacomelli, Roberto, Arcarese, Luisa, Guggino, Giuliana, Russo, Romualdo, Puenpatom, Amy, Capocotta, Domenico, Nacci, Francesca, Anelli, Maria Grazia, Picerno, Valentina, Binetti, Corrado, Iannone, Florenzo |
| المساهمون: | D'Angelo, Salvatore, Tirri, Enrico, Giardino, Angela Maria, Derosa, Tiziana, Matucci‐cerinic, Marco, Dagna, Lorenzo, Santo, Leonardo, Ciccia, Francesco, Frediani, Bruno, Govoni, Marcello, Pallavicini, Francesca Bobbio, Grembiale, Rosa Daniela, Sedie, Andrea Delle, Mulè, Rita, Cantatore, Francesco Paolo, Foti, Rosario, Gremese, Elisa, Conigliaro, Paola, Salaffi, Fausto, Viapiana, Ombretta, Cauli, Alberto, Giacomelli, Roberto, Arcarese, Luisa, Guggino, Giuliana, Russo, Romualdo, Puenpatom, Amy, Capocotta, Domenico, Nacci, Francesca, Anelli, Maria Grazia, Picerno, Valentina, Binetti, Corrado, Iannone, Florenzo |
| سنة النشر: | 2024 |
| المجموعة: | Università degli Studi di Ferrara: CINECA IRIS |
| الوصف: | A high proportion of patients may fail a first-line anti-TNF drug, necessitating the switch to another anti-TNF treatment. After 12 months of GLM treatment, 80% of RA patients achieved low disease activity (LDA), 37.1% with PsA achieved minimal disease activity and 55.3% with axSpA achieved LDA while persistence at 12 months in all patients was 77.7%. In this 1-year analysis of the GOBEYOND study in Italy, GLM had a favorable benefit: risk profile and high retention rate in patients with PsA, RA and axSpA. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | STAMPA |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/38433479; info:eu-repo/semantics/altIdentifier/wos/WOS:001193252700004; volume:27; issue:3; firstpage:e15091-1; lastpage:e15091-7; numberofpages:7; journal:INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES; https://hdl.handle.net/11392/2544870Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85186890388 |
| DOI: | 10.1111/1756-185x.15091 |
| DOI: | 10.1111/1756-185X.15091 |
| الإتاحة: | https://doi.org/10.1111/1756-185x.15091Test https://hdl.handle.net/11392/2544870Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.D6707274 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1111/1756-185x.15091 |
|---|